Advanced Search

 

Study ID Status Title Patient Level Data
S3B10939 Completed An open-label, single-dose, randomized, two-period cross-over trial to evaluate the effect of alosetron administration (1 mg PO) on the pharmacokinetics of ibuprofen (600 mg PO) administration in healthy subjects.
S3B10940 Completed A randomised, double-blind, placebo-controlled, cross-over study to investigate the effect of alosetron (GR68755C) on basal jejunal water and electrolyte transport in healthy male subjects.
S3B10942 Completed An open-label study of the pharmacokinetics of a single 1mg oral dose of alosetron in healthy Korean subjects.
S3B10945 Completed A Double-Blind, Randomised, 2-Way Crossover Study to Determine the Effect of Alosetron 1mg BID for 14 days Versus Placebo BID on Visceral Hypersensitivity Following Duodenal Lipid Infusion in Female Diarrhea-Predominant IBS Patients
S3B10946 Completed An open-label parallel-group, pharmacokinetics and tolerability study of a single 1mg oral dose of alosetron in hepatically impaired subjects and in healthy control subjects.
S3B10947 Completed An Open-Label, Non-Randomized, Mass Balance Study to Characterize the Metabolism of Isotopically Labelled Alosetron After a Single 4mg Oral Dose of [13C, 14C]-Alosetron in Healthy Subjects
S3B10948 Completed An open-label, Within-Subject Study to Compare the Pharmacodynamics and Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel 100mg and Ethinyl Estradiol 20mg in Healthy Female Subjects When Administered Alone and Following Co-Administration of Alosetron 1mg BID Orally for 28 Days
S3B20019 Completed A randomized, double-blind, placebo-controlled, crossover evaluation of the effects of GR68755C on plasma levels of haloperidol in patients with a diagnosis of schizophrenia.
S3B20023 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess the Clinical Efficacy of Alosetron (GR68755) in Male Subjects With Irritable Bowel Syndrome
S3B20032 Completed A four-week, open, multicenter study to assess the safety and efficacy of 1 mg once daily (QD) of GR68755 in female subjects with severe diarrhea-predominant irritable bowel syndrome (IBS) who have frequent bowel urgency
S3B30006 Completed A 1-Year Randomized, Double-Blind, Placebo-Controlled Study of Alosetron (GR68755) 1mg BID in Female Subjects With Irritable Bowel Syndrome
S3B30011 Completed A Twelve Week Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Alosetron Hydrochloride 1mg Twice Daily for Control of Bowel Urgency in Females with Nonconstipated Irritable Bowel Syndrome
S3B30012 Completed A 6-Week Trial of Alosetron Hydrochloride 1mg Twice Daily as Empirical Therapy in Female Subjects With Symptoms of Non-Constipated Irritable Bowel Syndrome
S3B30013 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron in Female Subjects With Alternating Diarrhea/Constipation Irritable Bowel Syndrome
S3B30015 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron in Non-Constipated Adolescents With Irritable Bowel Syndrome
S3B30017 Completed A Multi-Centre Study to Determine the Efficacy and Safety of Alosetron 2mg BID in Female Subjects With Diarrhoea-Predominant Irritable Bowel Syndrome who do not Respond to Treatment With Alosetron 1mg BID
S3B30019 Completed A 16-week, Open-label, Safety Study of Alosetron in Non-Constipated Adolescents with Irritable Bowel Syndrome
S3B30020 Completed A 24-Week Randomized, Open Label Study of Healthcare Resource Use, Quality of Life, and Productivity With Alosetron 1mg Twice Daily Versus Traditional Therapy in Females with Irritable Bowel Syndrome Whose Predominant Bowel Symptom is Diarrhea
S3B30025 Completed A 24-Week Randomised, Double-Blind, Placebo-Controlled Study of Quality of Life With Alosetron 1mg bd Versus Placebo in Females With Non-Constipated Irritable Bowel Syndrome
S3B30026 Completed 8-Week, Multicenter, Randomized Double-Blind Trial on Nonconstipated Patients with Irritable Bowel Syndrome Treated with 1mg Alosetron Twice A Day Compared to 2mg Alosetron Once A Day.
S3B30028 Completed An International, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study of Alosetron 1mg BID in Female Subjects With Diarrhoea-Predominant Irritable Bowel Syndrome Within Asia Pacific
S3B30031 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Study of Alosetron in Female Subjects With Non-Constipated Irritable Bowel Syndrome Who Show Therapeutic Response to Alosetron
S3B30040 Completed A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects with Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy
S3B30048 Completed A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy
S3B40031 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Alosetron Hydrochloride 1mg Twice Daily for Control of Bowel Urgency in Females with Non-constipated Irritable Bowel Syndrome in an Independent Practitioner Association (IPA) Model

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.